Intermagnetics appoints new president
Glenn Epstein has been named president and COO of Intermagnetics General of Latham, NY, with responsibility for day-to-day operations. He was previously president of Oxford Instrument's nuclear measurements group. He replaces Charles Dannemann, who
Glenn Epstein has been named president and COO of Intermagnetics General of Latham, NY, with responsibility for day-to-day operations. He was previously president of Oxford Instrument's nuclear measurements group. He replaces Charles Dannemann, who recently became COO of LNR Communications on Long Island, NY.
Intermagnetics also extended CEO Carl Rosner's employment contract. Rosner was slated to become a part-time employee as of May 31. His contract now calls for him to continue with Intermagnetics on a full-time basis through May 1999.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
